Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2i in Calcium Kidney Stones
NCT07055282Phase 1Recruiting
- Sponsor
- University of Chicago
- Start
- Nov 2025
- Primary completion
- Nov 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of empagliflozin in nephrolithiasis (2 arms), sponsored by University of Chicago. Primary endpoints: Change in calcium phosphate at 4 weeks, Change in urine citrate at 4 weeks and 2 more. Started Nov 2025; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
nephrolithiasis
Beyond the preview
Go deeper on NCT07055282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07055282.